| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 7 | | | |
| | | | | 19 | | | |
| | | | | 21 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 33 | | |
Name
|
| |
Age
|
| |
Position
|
| |
Date Appointed
|
|
Nevan Charles Elam | | |
56
|
| | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | | January 31, 2013 | |
Gil Labrucherie | | |
52
|
| | Director | | | November 20, 2019 | |
Nerissa Kreher, M.D. | | |
51
|
| | Director | | | March 2, 2021 | |
Philippe Fauchet | | |
66
|
| | Director | | | September 10, 2020 | |
Wladimir Hogenhuis, M.D.
|
| |
59
|
| | Director | | | March 2, 2021 | |
Young-Jin Kim | | |
67
|
| | Director | | | February 10, 2019 | |
Total Number of Directors
|
| |
6
|
| |||||||||
| | |
Male
|
| |
Female
|
| ||||||
Part I: Gender Identity | | | | | | | | | | | | | |
Directors
|
| | | | 5 | | | | | | 1 | | |
Part II: Demographic Background | | | | | | | | | | | | | |
White
|
| | | | 3 | | | | | | 1 | | |
African American or Black
|
| | | | 1 | | | | | | — | | |
Asian
|
| | | | 1 | | | | | | — | | |
Did Not Disclose Demographic Background
|
| | | | — | | | | | | — | | |
Directors who are Military Veterans
|
| | | | 1 | | | | | | — | | |
| | |
Committee Appointments
|
| |||||||||||||||
Director Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating
and Governance |
| |||||||||
Committee Members as of June 30, 2023: | | | | | | | | | | | | | | | | | | | |
Gil Labrucherie(1)
|
| | |
|
X
|
| | | |
|
X
|
| | | |
|
X
|
| |
Nerissa Kreher(4)
|
| | | | | | | | |
|
X
|
| | | |
|
X
|
| |
Philippe Fauchet(2)
|
| | |
|
X
|
| | | |
|
X
|
| | | |
|
X
|
| |
Wladimir Hogenhuis(3)
|
| | |
|
X
|
| | | |
|
X
|
| | | |
|
X
|
| |
Young-Jin Kim(5)
|
| | | | | | | | | | | | | | | | | | |
Name
|
| |
Fees Earned
or Paid in Cash ($) |
| |
Option
Awards ($) |
| |
Total ($)
|
| |||||||||
Gil Labrucherie
|
| | | | 69,000(1) | | | | | | —(6) | | | | | | 69,000 | | |
Nerissa Kreher
|
| | | | 62,000(2) | | | | | | —(6) | | | | | | 62,000 | | |
Philippe Fauchet
|
| | | | 66,000(3) | | | | | | —(6) | | | | | | 66,000 | | |
Wladimir Hogenhuis
|
| | | | 69,000(4) | | | | | | —(6) | | | | | | 69,000 | | |
Young-Jin Kim
|
| | | | 33,750(5) | | | | | | —(6) | | | | | | 33,750 | | |
| | |
Shares Underlying
Options Outstanding |
| |||||||||
| | |
Vested
|
| |
Unvested
|
| ||||||
Gil Labrucherie
|
| | | | 37,999 | | | | | | 55,001 | | |
Nerissa Kreher
|
| | | | 33,332 | | | | | | 56,668 | | |
Philippe Fauchet
|
| | | | 35,110 | | | | | | 54,890 | | |
Wladimir Hogenhuis
|
| | | | 33,332 | | | | | | 56,668 | | |
Young-Jin Kim
|
| | | | 13,333 | | | | | | 26,667 | | |
Name of Beneficial Owner
|
| |
Position with Company
|
| |
Beneficial
Ownership |
| |
Percent of
Class |
| ||||||
Stockholders in excess of 5% | | | | | | | | | | | | | | | | |
Entities associated with Federated Hermes, Inc.
|
| |
Stockholder
|
| | | | 8,373,274(1) | | | | | | 19.99% | | |
Handok, Inc.
|
| |
Stockholder
|
| | | | 5,942,617(2) | | | | | | 14.81% | | |
Nantahala Capital Management LLC
|
| |
Stockholder
|
| | | | 4,118,164(3) | | | | | | 9.99% | | |
Vivo Opportunity Fund Holdings, L.P.
|
| |
Stockholder
|
| | | | 3,242,842(4) | | | | | | 8.08% | | |
Stonepine Capital Management, LLC
|
| |
Stockholder
|
| | | | 2,768,656(5) | | | | | | 6.90% | | |
Directors and Executive Officers: | | | | | | | | | | | | | | | | |
Nevan Charles Elam
|
| |
Chief Executive Officer,
Acting Chair of the Board of Directors |
| | | | 1,792,399(6) | | | | | | 4.28% | | |
Gil Labrucherie
|
| |
Director
|
| | | | 120,044(7) | | | | | | * | | |
Nerissa Kreher
|
| |
Director
|
| | | | 63,333(8) | | | | | | * | | |
Philippe Fauchet
|
| |
Director
|
| | | | 63,555(9) | | | | | | * | | |
Wladimir Hogenhuis
|
| |
Director
|
| | | | 96,026(10) | | | | | | * | | |
Young-Jin Kim
|
| |
Director
|
| | | | 6,083,622(11) | | | | | | 15.15% | | |
Brian Roberts
|
| |
Chief Medical Officer
|
| | | | 488,231(12) | | | | | | 1.20% | | |
Daron Evans
|
| |
Chief Financial Officer
|
| | | | 159,900(13) | | | | | | * | | |
Directors and executive officers as a group (8 people)
|
| | | | | | | 8,867,110(14) | | | | | | 20.80% | | |
| | |
Plan Termination
Date |
| |
Shares to be Issued Upon
Exercise of Outstanding Options |
| |
Securities
Available For Future Issuance |
| ||||||||||||
| | |
Number of
Shares |
| |
Weighted
Average Exercise Price |
| |||||||||||||||
Equity compensation plans approved by security holders:
|
| | | | | | | | | | | | | | | | | | | | | |
2015 Non-Qualified Stock Option Plan
|
| |
February 23, 2020
|
| | | | 17 | | | | | $ | 19.86 | | | | | | — | | |
2016 Non-Qualified Stock Option Plan
|
| |
October 31, 2021
|
| | | | 140 | | | | | | 16.62 | | | | | | — | | |
2021 Equity Incentive Plan
|
| |
March 31, 2031
|
| | | | 8,388 | | | | | | 4.09 | | | | | | 2,312 | | |
2022 Employee Stock Purchase Plan
|
| |
Indefinite
|
| | | | — | | | | | | — | | | | | | 500 | | |
Equity compensation plans not approved by security holders:
|
| | | | | | | | | | | | | | | | | | | | | |
2019 Non-Qualified Stock Option Plan
|
| |
July 31, 2029
|
| | | | 200 | | | | | | 14.50 | | | | | | — | | |
Total
|
| | | | | | | 8,745 | | | | | | 4.56 | | | | | | 2,812 | | |
| | |
2023
|
| |
2022
|
| ||||||||||||||||||
| | |
Amount
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| ||||||||||||
Audit fees(1)
|
| | | $ | 190,000 | | | | | | 84% | | | | | $ | 259,00 | | | | | | 85% | | |
Tax fees
|
| | | | 36,550 | | | | | | 16% | | | | | | 47,255 | | | | | | 15% | | |
Total
|
| | | $ | 226,550 | | | | | | 100% | | | | | $ | 306,225 | | | | | | 100% | | |
Name
|
| |
Age
|
| |
Position
|
| |
Date Appointed
|
|
Nevan Charles Elam | | |
56
|
| | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | |
January 31, 2013
|
|
Brian Roberts | | |
49
|
| | Chief Medical Officer | | |
June 1, 2022
|
|
Daron Evans | | |
50
|
| | Chief Financial Officer | | |
January 23, 2024
|
|
Name and Position(9)
|
| |
Fiscal
Year |
| |
Salary
|
| |
Bonus
|
| |
Stock
Option Awards |
| |
All Other
Compensation |
| |
Total
|
| ||||||||||||||||||
Nevan Charles Elam
Chief Executive Officer |
| | | | 2023 | | | | | $ | 534,112(1) | | | | | $ | 416,068(3) | | | | | $ | —(5) | | | | | $ | 23,466(6) | | | | | $ | 973,646 | | |
| | | 2022 | | | | | $ | 515,000(1) | | | | | $ | 378,750(4) | | | | | $ | 6,862,960(5) | | | | | $ | 24,590(6) | | | | | $ | 7,781,300 | | | ||
Brian Roberts, M.D.
Chief Medical Officer |
| | | | 2023 | | | | | $ | 457,809(2) | | | | | $ | 237,753(3) | | | | | $ | —(5) | | | | | $ | 43,296(7) | | | | | $ | 738,858 | | |
| | | 2022 | | | | | $ | 401,500(2) | | | | | $ | 121,875(4) | | | | | $ | 1,847,720(5) | | | | | $ | 52,053(8) | | | | | $ | 2,423,148 | | |
| | | | | | | | |
Number of Securities
Underlying Unexercised Options |
| |
Option
Exercise Price |
| |
Option
Expiration Date |
| |||||||||||||||
Name
|
| |
Grant Date
|
| |
Exercisable
|
| |
Unexercisable
|
| |||||||||||||||||||||
Nevan Charles Elam
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 7/31/19 | | | | | | 200,000 | | | | | | — | | | | | $ | 14.50 | | | | | | 7/31/29 | | | ||
| | | 6/14/21 | | | | | | 250,000 | | | | | | 125,000(1) | | | | | | 12.28 | | | | | | 6/14/31 | | | ||
| | | 6/23/22 | | | | | | 650,000 | | | | | | 1,950,00(3) | | | | | | 3.40 | | | | | | 6/23/32 | | | ||
Total for Mr. Elam
|
| | | | | | | | | | 1,100,000 | | | | | | 2,075,000 | | | | | | | | | | | | | | |
Brian Roberts, M.D.
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 7/31/19 | | | | | | 40,000 | | | | | | — | | | | | $ | 14.50 | | | | | | 7/31/29 | | | ||
| | | 6/14/21 | | | | | | 56,250 | | | | | | 18,750(2) | | | | | | 12.28 | | | | | | 6/14/31 | | | ||
| | | 6/23/22 | | | | | | 175,00 | | | | | | 525,00(3) | | | | | | 3.40 | | | | | | 6/23/32 | | | ||
Total for Dr. Roberts
|
| | | | | | | | | | 271,250 | | | | | | 543,750 | | | | | | | | | | | | | | |
Pay Versus Performance
|
| ||||||||||||||||||||||||||||||||||||
Year(1)
|
| |
Summary
Compensation Table Total for PEO(2) |
| |
Compensation
Actually Paid to PEO(3) |
| |
Average
Summary Compensation Table Total for Non-PEO NEOs(2) |
| |
Average
Compensation Actually Paid to Non-PEO NEOs(4) |
| |
Value of Initial
Fixed $100 Investment Based On Rezolute Total Stockholder Return(5) |
| |
Net Income(6)
|
| ||||||||||||||||||
2023
|
| | | $ | 973,646 | | | | | $ | (1,958,066) | | | | | $ | 738,858 | | | | | $ | (30,316) | | | | | $ | 14 | | | | | $ | (51,787,000) | | |
2022
|
| | | $ | 7,781,300 | | | | | $ | 3,572,820 | | | | | $ | 2,423,148 | | | | | $ | 1,699,320 | | | | | $ | 23 | | | | | $ | (41,060,000) | | |
PEO
|
| ||||||||||||||||||
| | | | | | | | |
2022
|
| |
2023
|
| ||||||
| | |
Summary Compensation Table – Total Compensation
|
| |
(a)
|
| | | $ | 7,781,300 | | | | | $ | 973,646 | | |
- | | |
Grant Date Fair Value of Stock Awards and Option Awards Granted in Fiscal Year
|
| |
(b)
|
| | | $ | 6,862,960 | | | | | $ | 0 | | |
+ | | |
Fair Value at Covered Fiscal Year End of All Outstanding and Unvested Stock Awards and Option Awards Granted in Covered Fiscal Year
|
| |
(c)
|
| | | $ | 6,237,785 | | | | | $ | 0 | | |
+ | | |
Change in Fair Value as of Prior Fiscal Year End of Any
Outstanding and Unvested Stock Awards and Option Awards Granted in Any Prior Fiscal Year |
| |
(d)
|
| | | $ | (2,393,356) | | | | | $ | (2,265,885) | | |
+ | | |
Fair Value at Vesting Date of Stock Awards and Option Awards
Granted in Covered Fiscal Year That Vested During Covered Fiscal Year |
| |
(e)
|
| | | $ | 0 | | | | | $ | 0 | | |
+ | | |
Change in Fair Value as of Vesting Date of Any Stock Awards and Option Awards Granted in Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied at End of or During Covered Fiscal Year
|
| |
(f)
|
| | | $ | (1,189,949) | | | | | $ | (665,827) | | |
- | | |
Fair Value as of Prior Fiscal Year End of Any Stock Awards and
Option Awards Granted in Any Prior Fiscal Year That Failed to Meet Applicable Vesting Conditions During Covered Fiscal Year |
| |
(g)
|
| | | $ | 0 | | | | | $ | 0 | | |
= | | |
Compensation Actually Paid
|
| | | | | | $ | 3,572,820 | | | | | -$ | 1,958,066 | | |
NEO Average
|
| ||||||||||||||||||
| | | | | | | | |
2022
|
| |
2023
|
| ||||||
| | |
Summary Compensation Table – Total Compensation
|
| |
(a)
|
| | | $ | 2,423,148 | | | | | $ | 738,858 | | |
- | | |
Grant Date Fair Value of Stock Awards and Option Awards Granted in Fiscal Year
|
| |
(b)
|
| | | $ | 1,847,720 | | | | | $ | 0 | | |
+ | | |
Fair Value at Covered Fiscal Year End of All Outstanding and Unvested Stock Awards and Option Awards Granted in Covered Fiscal Year
|
| |
(c)
|
| | | $ | 1,679,404 | | | | | $ | 0 | | |
+ | | |
Change in Fair Value as of Prior Fiscal Year End of Any
Outstanding and Unvested Stock Awards and Option Awards Granted in Any Prior Fiscal Year |
| |
(d)
|
| | | $ | (360,815) | | | | | $ | (598,192) | | |
+ | | |
Fair Value at Vesting Date of Stock Awards and Option Awards
Granted in Covered Fiscal Year That Vested During Covered Fiscal Year |
| |
(e)
|
| | | $ | 0 | | | | | $ | 0 | | |
+ | | |
Change in Fair Value as of Vesting Date of Any Stock Awards and Option Awards Granted in Any Prior Fiscal Year For Which All Applicable Vesting Conditions Were Satisfied at End of or During Covered Fiscal Year
|
| |
(f)
|
| | | $ | (194,697) | | | | | $ | (170,982) | | |
- | | |
Fair Value as of Prior Fiscal Year End of Any Stock Awards and
Option Awards Granted in Any Prior Fiscal Year That Failed to Meet Applicable Vesting Conditions During Covered Fiscal Year |
| |
(g)
|
| | | $ | 0 | | | | | $ | 0 | | |
= | | |
Compensation Actually Paid
|
| | | | | | $ | 1,699,320 | | | | | $ | (30,316) | | |